Last reviewed · How we verify
WSD0922-FU
At a glance
| Generic name | WSD0922-FU |
|---|---|
| Also known as | WSD0922 |
| Sponsor | Wayshine Biopharm, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases (PHASE1)
- A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC (PHASE1, PHASE2)
- A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer (PHASE2)
- A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |